Pomalyst
FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors »
"The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved t"...
Read the FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors article »
Pomalyst
OVERDOSE
No specific information is available on the treatment of overdose with pomalidomide, and it is unknown whether pomalidomide or its metabolites are dialyzable.
CONTRAINDICATIONS
Pregnancy
POMALYST can cause fetal harm when administered to a pregnant female [see WARNINGS AND PRECAUTIONS and Use in Specific Populations]. POMALYST is contraindicated in females who are pregnant. Pomalidomide is a thalidomide analogue, and is teratogenic in both rats and rabbits when administered during the period of organogenesis. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.
Last reviewed on RxList: 2/21/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Pomalyst Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Cancer
Get the latest treatment options.
Updated & New
